checkAd

     397  0 Kommentare Claritas Pharmaceuticals (formerly Kalytera Therapeutics) to Focus on Development of R-107 as a Therapy for Vaccine-Resistant COVID-19, Influenza, and Other Viral Infections - Seite 4

    Contact Information
    Robert Farrell
    President, CEO
    (888) 861-2008
    info@claritas.co

    1 Nathan C., Xie Q.W. Nitric oxide synthases: roles, tolls, and controls. Cell. 1994;78:915–918. doi: 10.1016/0092-8674(94)90266-6. [PubMed] [CrossRef] [Google Scholar]

    Lesen Sie auch

    2 SaNOtize Research and Development Corp., Press Release dated April 22, 2020: New Laboratory Tests Conducted by Utah-Based Institute for Antiviral Research Confirm SaNOtize’s Nitric Oxide Releasing Solution (NORSTM) is Over 99.9% Effective Against SARS-CoV-2, the Virus that Causes COVID-19



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 4 von 4

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Claritas Pharmaceuticals (formerly Kalytera Therapeutics) to Focus on Development of R-107 as a Therapy for Vaccine-Resistant COVID-19, Influenza, and Other Viral Infections - Seite 4 SAN FRANCISCO and TORONTO, March 01, 2021 (GLOBE NEWSWIRE) - Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.), (TSX VENTURE EXCHANGE: KLY and OTC: KALTF) (the "Company" or "Claritas") today announced that the Company will …